Avandia news from FiercePharma
NewsSafety questions on Fosamax, Actos, et al.
It must be tough for pharma execs to open a newspaper these days. If reporters aren't going on about Read more...
GSK, Schering-Plough profits drop
When big drugs tank, they take their makers down with them. Witness first-quarter reports from GlaxoSmithKline and Schering-Plough. GSK is suffering on a Read more...
GSK rebuked for missing Avandia reports
GlaxoSmithKline got a trip to the FDA woodshed for failing to regularly report post-marketing data it was gathering on the diabetes med Avandia. GSK failed to include updates on as many as 18 Read more...
Scottish docs call for Avandia freeze
Some doctors in Scotland want to put Avandia in cold storage. National Health Service consultants are recommending that docs stop prescribing the diabetes med to patients with heart problems, The Read more...
Could full data disclosure avert scandal?
New calls for old drug data in the U.K. have experts second-guessing big drug-safety scandals. If scientists and regulators had had access to every bit of data on Vioxx from the get-go, for instance, Read more...
Ranks of sales reps thinning
Fewer reps are knocking on doctors' doors these days. A consulting firm that advises most of Big Pharma says Read more...
GAO to probe FDA's post-market follow-up
The government's own watchdog will soon be sniffing around FDA drug approvals and FDA-ordered post-marketing studies. Prompted by Sen. Charles Grassley, the Government Accountability Office plans to Read more...
SPOTLIGHT: Drug scandals cause second-guessing
Recent drug news--from Zyprexa's weight gain-and-diabetes problem to Avandia's heart attack warning to the recent hoopla over Vytorin--have some people asking whether drug therapy is all it's Read more...
Consensus: GSK's Witty faces uphill slog
Incoming GlaxoSmithKline CEO Andrew Witty has a tough job. He's inheriting the company at a time when Avandia safety questions are dragging down sales and when generic competition is circling five Read more...
Avandia drop-off erodes GSK profits
Plummeting Avandia sales are taking their toll on GlaxoSmithKline's bottom line. The company reported a 12 percent drop in fourth quarter net, to $2.08 billion, on flat revenues of $11.62 billion. Read more...
| Press ReleasesPRESS RELEASE: GlaxoSmithKline responds to JAMA article GlaxoSmithKline responds to JAMA article on the ICES Thiazolidinediones and Cardiovascular Outcomes in Older Patients with Diabetes 11 December 2007 - The following is GlaxoSmithKline’s [NYSE: Read more... PRESS RELEASE: GlaxoSmithKline revises US labeling for Avandia GlaxoSmithKline revises US labeling for Avandia GlaxoSmithKline announced today that it is implementing changes to the US product label for Avandia® (rosiglitazone maleate), based on an extensive Read more... PRESS RELEASE: FDA Adds Boxed Warning for Heart Attacks to Anti-Diabetes Drug Avandia FDA Adds Boxed Warning for Heart Attacks to Anti-Diabetes Drug Avandia Agency says drug to remain on market, while safety assessment continues The U.S. Food and Drug Administration announced today Read more... PRESS RELEASE: GlaxoSmithKline responds to JAMA articles GlaxoSmithKline responds to JAMA articles PHILADELPHIA, PA–September 11, 2007 - GlaxoSmithKline believes that conclusions drawn from the most recent meta-analyses published by Drs. Nissen et. al. Read more... |
Get more Avandia coverage at:
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight